⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30952788 | 1.00 | — | — | |
| SCHEMBL91229 | 0.79 | — | — | |
| SCHEMBL29598727 | 0.79 | — | — | |
| SCHEMBL69524 | 0.75 | — | — | |
| SCHEMBL14413 | 0.75 | — | — | |
| SCHEMBL30411804 | 0.75 | — | — | |
| SCHEMBL29392814 | 0.75 | — | — | |
| SCHEMBL2840953 | 0.75 | — | — | |
| SCHEMBL29350499 | 0.75 | — | — | |
| SCHEMBL11226552 | 0.75 | CA9 (0.65) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1191 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116478199-A | Bimetallic catalyst and preparation method thereof, and preparation method of high molecular weight olefin polymer | 万华化学集团股份有限公司 | 2023-07-25 | — | — | CN | claimed |
| US-20060004123-A1 | PHASE CHANGE INK PRINTING PROCESS | XEROX CORPORATION | 2006-01-05 | — | — | US | claimed |
| CN-122059918-A | Synthesis method and application of cyclobutane chroman skeleton molecular compound | 昆明理工大学 | 2026-05-19 | — | — | CN | disclosed |
| US-20260125378-A2 | Heterocyclic Compounds | BEONE MEDICINES I GMBH (CH) | 2026-05-07 | — | — | US | disclosed |
| US-12617802-B2 | Sulfonimidamide compounds as NLRP3 modulators | GENENTECH, INC. (US) | 2026-05-05 | — | — | US | disclosed |
| WO-2026090477-A1 | HELICASE INHIBITORS AND USES THEREOF | KIMIA THERAPEUTICS, INC. (US) | 2026-04-30 | — | — | WO | disclosed |
| EP-4720038-A1 | (HETERO)ARYL-CARBONYL-HETEROBICYCLIC COMPOUNDS AS INHIBITORS OF PMS2 FOR CANCER AND DEGENERATIVE ILLNESSES | Neophore Limited (GB) | 2026-04-08 | — | — | EP | disclosed |
| EP-4703359-A1 | IMIDAZOPYRIDINE OR IMIDAZOPYRAZINE COMPOUND, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF | Shanghai Simr Biotechnology Co., Ltd. (CN) | 2026-03-04 | — | — | EP | disclosed |
| EP-4699607-A2 | N-(HYDROXYALKYL (HETERO)ARYL) TETRAHYDROFURAN CARBOXAMIDES AS MODULATORS OF SODIUM CHANNELS | Vertex Pharmaceuticals Incorporated (US) | 2026-02-25 | — | — | EP | disclosed |
| US-12528802-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2026-01-20 | — | — | US | disclosed |
| US-12522619-B2 | Inhibitors of complement factors and uses thereof | ANNEXON, INC. (US) | 2026-01-13 | — | — | US | disclosed |
| US-5688808-A | Steroid receptor modulator compounds and methods | LIGAND PHARMACEUTICALS INCORPORATED (US) | 1997-11-18 | — | — | US | disclosed |
| WO-1997042183-A1 | BENZOFURYL DERIVATIVES AND THEIR USE | F. HOFFMANN-LA ROCHE AG (CH) | 1997-11-13 | — | — | WO | disclosed |
| EP-0800519-A1 | STEROID RECEPTOR MODULATOR COMPOUNDS AND METHODS | LIGAND PHARMACEUTICALS, INC. (US) | 1997-10-15 | — | — | EP | disclosed |
| CN-1140174-A | Piperidine derivatives, process for preparation thereof and application thereof in therapeutics | SYNTHELABO (FR) | 1997-01-15 | — | — | CN | disclosed |
| EP-0732334-A1 | Piperidine derivatives, process for their preparation and their therapeutic application | SYNTHELABO (FR) | 1996-09-18 | — | — | EP | disclosed |
| WO-1996019458-A2 | STEROID RECEPTOR MODULATOR COMPOUNDS AND METHODS | LIGAND PHARMACEUTICALS INCORPORATED (US) | 1996-06-27 | — | — | WO | disclosed |
| CN-1070400-A | Benzoglyoxaline | FISONS PLC (GB) | 1993-03-31 | — | — | CN | disclosed |
| WO-1993002077-A1 | BENZIMIDAZOLES | FISONS PLC (GB) | 1993-02-04 | — | — | WO | disclosed |
| EP-0526033-A1 | Benzimidazoles | FISONS plc (GB) | 1993-02-03 | — | — | EP | disclosed |